Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

Phase 1

Completed

Conditions: Endometrial Clear Cell Carcinoma
Stage IIA Cervical Cancer
Stage IVA Cervical Cancer
Cervical Squamous Cell Carcinoma
Stage II Endometrial Carcinoma
Cervical Small Cell Carcinoma
Stage I Endometrial Carcinoma
Stage IB Cervical Cancer
Stage IIB Cervical Cancer
Stage III Cervical Cancer

Interventions: Radiation: fludeoxyglucose F 18
Procedure: positron emission tomography
Procedure: computed tomography
Drug: ferumoxtran-10
Procedure: magnetic resonance imaging
Procedure: diagnostic lymphadenectomy
Procedure: lymph node biopsy

First Posted Date: 2006-12-28

Last Posted Date: 2019-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 384

Registration Number: NCT00416455

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
The Hospital of Central Connecticut, New Britain, Connecticut, United States

and more 30 locations

Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A
Untreated Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Acute Myeloid Leukemia

Interventions: Procedure: Autologous Bone Marrow Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Decitabine
Drug: Etoposide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2006-12-28

Last Posted Date: 2019-02-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 546

Registration Number: NCT00416598

Locations: 🇺🇸
Northwell Health NCORP, Lake Success, New York, United States
🇺🇸
Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States
🇺🇸
University of Illinois, Chicago, Illinois, United States

and more 43 locations

Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: eribulin mesylate
Drug: cisplatin
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-12-22

Last Posted Date: 2014-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00415324

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
University of Southern California/Norris Cancer Center, Los Angeles, California, United States
🇺🇸
University of California at Davis Cancer Center, Sacramento, California, United States

and more 1 locations

Energy Metabolism and Nutrient Absorption in Lean and Obese Individuals

Completed

Conditions: Obesity

First Posted Date: 2006-12-21

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 28

Registration Number: NCT00414063

Locations: 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States

Chordoma Family Study

Completed

Conditions: Chordoma

First Posted Date: 2006-12-13

Last Posted Date: 2019-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT00410670

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma

Phase 2

Completed

Conditions: Stage II Multiple Myeloma
Multiple Myeloma in Relapse
Stage III Multiple Myeloma

Interventions: Biological: bevacizumab
Drug: lenalidomide
Drug: dexamethasone

First Posted Date: 2006-12-13

Last Posted Date: 2017-09-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00410605

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

Insulin Secretory Defects in Pima Indians at High Risk for NIDDM

Completed

Conditions: NIDDM

First Posted Date: 2006-12-13

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 310

Registration Number: NCT00410800

Locations: 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Non-small Cell Lung Cancer

Interventions: Drug: cediranib maleate
Drug: pemetrexed disodium

First Posted Date: 2006-12-13

Last Posted Date: 2018-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00410904

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States

Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery

Phase 1

Completed

Conditions: Stage III Ovarian Cancer AJCC v6 and v7
Recurrent Uterine Corpus Carcinoma
Stage III Uterine Corpus Cancer AJCC v7
Recurrent Ovarian Carcinoma
Stage IV Ovarian Cancer AJCC v6 and v7
Stage IV Uterine Corpus Cancer AJCC v7
Adult Solid Neoplasm

Interventions: Drug: Eribulin Mesylate
Drug: Gemcitabine Hydrochloride

First Posted Date: 2006-12-13

Last Posted Date: 2018-10-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00410553

Locations: 🇨🇦
Ottawa Hospital-Civic Campus, Ottawa, Ontario, Canada
🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

Cancer Risk in X-Ray Technologists: Second Survey

Completed

Conditions: Radiation-Induced Neoplasms
Thyroid+Neoplasm+Radiation+Etiology
Breast+Neoplasm+Radiation+Etiology

First Posted Date: 2006-12-13

Last Posted Date: 2020-04-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 146022

Registration Number: NCT00410475

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy